A Phase 2 interventional study of NAC 900mg/day and NAC 3600mg/day in Chronic Fatigue Syndrome and Myalgic Encephalomyelitis, sponsored by Weill Medical College of Cornell University. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Weill Medical College of Cornell University · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Fatigue Syndrome, Chronic with a site in United States — 21 open to participants now, 24 under way, none of them phase 3. Fatigue Syndrome, Chronic · United States.
Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, this one is the 17th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2020, is one of 12 in phase 2, reaches primary completion later than 10 of the 23 other live ones, and was the 54th registered.
265 studies on the registry are indexed under Fatigue Syndrome, Chronic; 63 are open to participants now.
Browse Fatigue Syndrome, Chronic studies →21 of the 86 studies in Fatigue Syndrome, Chronic with a site in United States are open now. Recruiting first, the newest first:
Fred Friedberg · Sites in United States
Ages 18–65
University of Alabama at Birmingham · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
IMMUNOe Research Centers · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Fatigue Syndrome, Chronic studies recruiting now, 19 (42%) set no upper age limit and 20 (44%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 21 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 17 · Phase 3 1 · Phase 4 5
First in 1994; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 95 is above the median of 60 across 179 interventional studies indexed under Fatigue Syndrome, Chronic.
Median enrollment 50 across the 58 interventional studies, 152 across the 26 observational. Of the 47 that completed or were terminated, 15 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 86 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Weill Medical College of Cornell University has 1 study filed under Fatigue Syndrome, Chronic — fewer than ten, so there is no comparison to draw.
10 of the studies in Fatigue Syndrome, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06585254Icahn School of Medicine at Mount SinaitVNS in Long COVID-19 | 2026-12-31 |
| NCT04049331Seattle Institute for Biomedical and Clinical ResearchTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | 2027-01-30 |
| NCT04542161Weill Medical College of Cornell UniversityAssessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2027-04-30 |
| NCT07600320Icahn School of Medicine at Mount SinaiFareon Open Label Device Clinical Trial | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) is an unexplained multisymptom/multisystem disorder for which there are currently no validated treatments. The present exploratory clinical trial aims to advance our understand of the mechanisms of in situ GSH synthesis control through assessment of the response of brain GSH and plasma markers of oxidative stress to different doses of NAC in comparison to placebo, as a potential treatment for ME/CFS that would provide neuroprotection against oxidative stress by restoring cortical GSH reserves. If successful, this exploratory clinical trial would address a significant public health concern by shedding new light onto the mechanisms of action of NAC in brain GSH restoration, which could open a new avenue for the development of potentially effective treatments for a disorder, ME/CFS, that currently has none.
This phase two, single-site study will utilize a double-blind, placebo-controlled, randomized, pre-/post-treatment design to investigate the effect of NAC dosing on brain GSH levels and measure temporally concordant plasma levels of several established circulating markers of oxidative stress. Three study groups, of 20 subjects each (for a total of 60 who completed all components of the study), will each be administered a different dose (0 mg/day, 900mg/day, 3600mg/day) of the study intervention over a four week period; N-acetylcysteine (NAC) treatment. Subjects receiving 0 mg/day dose will be administered a placebo. Baseline visit assessments will include blood collection, survey questionnaires, MRI and MRS imaging. Subjects whose initial screening confirms low GSH level at baseline will be provided with a 4-week supplement of anonymized NAC or placebo caplets. After 4 weeks, subjects will then undergo a follow-up visit to repeat the baseline assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period
Drug: NAC 900mg/day
Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period
Drug: NAC 3600mg/day
Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period
Drug: NAC 0mg/day (Placebo)
Drug page: AcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
self administer NAC 900mg/day caplets for a four week period
Drug page: AcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
self administer NAC 3600mg/day caplets for a four week period
self administer NAC 0mg/day (placebo) caplets for a four week period
Change in GSH levels of treatment response: measure 1
Levels of occipital cortex GSH, as measured in vivo with 1H MRS
Time frame: pre/post 4 weeks of NAC supplementation
Change in GSH levels of treatment response: measure 2
Levels of striatal GSH, as measured in vivo with 1H MRS
Time frame: pre/post 4 weeks of NAC supplementation
Change of levels of ventricular CSF lactate of treatment response
Levels of ventricular CSF lactate, as measured in vivo with 1H MRS
Time frame: pre/post 4 weeks of NAC supplementation
Change of regional cerebral blood flow (rCBF) of treatment response
Regional cerebral blood flow (rCBF), as measured in vivo with perfusion MRI
Time frame: pre/post 4 weeks of NAC supplementation
Change in Oxidative stress levels of treatment response: measure 1
Level of F2-isoprostanes, a marker of oxidative stress, in plasma samples obtained
Time frame: pre/post 4 weeks of NAC supplementation
Change in Oxidative stress levels of treatment response: measure 2
Level of 8-hydroxy-2-deoxy guanosine (8-OH-2dG), a DNA damage marker, in plasma samples obtained
Time frame: pre/post 4 weeks of NAC supplementation
Change in Oxidative stress levels of treatment response: measure 3
Level of reduced (GSH) glutathione, an antioxidant capacity and redox state marker, in plasma obtained
Time frame: pre/post 4 weeks of NAC supplementation
Change in Oxidative stress levels of treatment response: measure 4
Level of oxidized (GSSG) glutathione, an antioxidant capacity and redox state marker, in plasma obtained
Time frame: pre/post 4 weeks of NAC supplementation
Change in Oxidative stress levels of treatment response: measure 5
Level of GSH peroxidase, an antioxidant enzyme activity marker, in plasma obtained
Time frame: pre/post 4 weeks of NAC supplementation
Change in Oxidative stress levels of treatment response: measure 6
Level of protein carbonyls, a protein damage marker, in plasma obtained
Time frame: pre/post 4 weeks of NAC supplementation
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2020 (actual). Primary completion is estimated for Apr 2027, 79 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetylcysteine
Weill Medical College of Cornell University →